In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does Alnylam Lift All Oligo Boats? The Dicerna IPO

Executive Summary

Dicerna’s debut stood out even in a hot market for biotech IPOs, but it is hard to sort out how much investor enthusiasm was driven by its specific technologies, rub-off from the recent Alnylam/ Sanofi-Genzyme deal, and demands of insiders who wanted liquidity but not dilution.

Advertisement

Related Content

Dicerna, Flush With Cash, Is Back To The Drawing Board
Biopharma Dealmaking Quarterly Statistics, Q1 2014
Financings Of The Fortnight And The Never-Ending Venture Round
How And Why Genzyme And Alnylam Expanded Their Alliance
From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit
Venture-Backed Dicerna Cuts First Pharma Deal as Prelude to 'B' Round

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel